Clinical Trial Update: A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients [Phase 3]

View source ↗

Summary

A long-term Phase 3 study of YM178 in patients with symptomatic overactive bladder has completed. The trial was sponsored by Astellas Pharma Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• YM178

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED